James Geoghegan

Title: James Geoghegan: Innovator in Cancer Treatment

Introduction

James Geoghegan is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of cancer treatment through his innovative work. With a total of 5 patents, Geoghegan has focused on developing binding molecules that target CD73, a protein associated with various cancers.

Latest Patents

One of Geoghegan's latest patents is titled "Binding molecules specific for CD73 and uses thereof." This patent provides a detailed disclosure of anti-CD73 binding molecules, including antibodies and their antigen-binding fragments. The patent outlines pharmaceutical formulations that incorporate these compositions and describes methods for diagnosing and treating diseases linked to CD73 expression, particularly cancer. The treatment approaches include direct therapy using the disclosed anti-CD73 binding molecules, adjuvant therapy with other anticancer agents, and combination therapies that may involve chemotherapy.

Career Highlights

James Geoghegan is currently employed at MedImmune Limited, where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions for cancer treatment, showcasing his commitment to improving patient outcomes.

Collaborations

Geoghegan collaborates with several talented individuals in his field, including Carl Hay and Kris Sachsenmeier. These partnerships enhance the research and development process, leading to more effective therapeutic options.

Conclusion

James Geoghegan's contributions to the field of cancer treatment through his innovative patents and collaborations highlight his dedication to advancing medical science. His work continues to pave the way for new therapeutic strategies that can significantly impact patient care.